MAX BioPharma

Executive Summary

MAX BioPharma is a privately-held, preclinical-stage biopharmaceutical company pioneering Oxysterol Therapeutics®—a novel class of small-molecule lipids targeting serious human diseases. Based in Los Angeles, the company was founded in 2003 and has built a pipeline addressing metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, chronic inflammation, viral infections, and orthopedic disorders. Its lead program focuses on MASH, a large and growing unmet need with no approved therapies. By leveraging the unique signaling properties of oxysterols, MAX BioPharma aims to modulate multiple disease pathways simultaneously, potentially offering advantages over single-target drugs. Despite being at the preclinical stage, the company's differentiated platform and long history suggest deep scientific expertise. However, as a private company with limited public information, development timelines and funding status remain opaque. Conviction is tempered by the early stage and lack of disclosed clinical data.

Upcoming Catalysts (preview)

• H2 2026Preclinical data from MASH program presented at a major medical conference40% success
• 2027IND filing for lead MASH candidate30% success
• 2026Partnership or licensing deal for one of its oxysterol programs35% success